Vaccine News and Research

Latest Vaccine News and Research

Scientists isolate and analyze antibody that neutralizes Sudan virus

Scientists from The Scripps Research Institute and the US Army's Medical Research Institute of Infectious Diseases have isolated and analyzed an antibody that neutralizes Sudan virus, a major species of ebolavirus and one of the most dangerous human pathogens.

20 Nov 2011

Recent scientific progress in developing new HIV/AIDS interventions

Kaitlin Christenson, coalition director for the Global Health Technologies Coalition, "reflects on recent progress made by the scientific community in developing new interventions to combat HIV/AIDS as a result of leadership from the U.S. government" in this ONE blog post.

19 Nov 2011

GAVI Alliance to fund roll-out of vaccines against cervical cancer, rubella in developing countries

The GAVI Alliance "has agreed to fund the roll-out of vaccines against cervical cancer in developing countries, offering protection against a disease that kills one woman every two minutes," Reuters reports.

19 Nov 2011

HVTN debunks top 10 myths about HIV vaccine research

Dec. 1 is World AIDS Day, and in commemoration of the occasion, the HIV Vaccine Trials Network, headquartered at Fred Hutchinson Cancer Research Center, debunks the top 10 myths about HIV vaccine research.

18 Nov 2011

Potential new ways to design vaccines, antibiotics

A University of Louisville scientist has determined for the first time how the bacterium that causes Legionnaires' disease manipulates our cells to generate the amino acids it needs to grow and cause infection and inflammation in the lungs.

18 Nov 2011

Inovio announces results from SynCon avian influenza vaccine Phase I study

Inovio Pharmaceuticals, Inc., which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a single intradermal (ID) electroporation boost of its SynCon avian influenza vaccine generated HAI titers against six different, unmatched strains of H5N1 - a distinct new clinical achievement on the global research community's path to develop universal influenza vaccines.

18 Nov 2011

Future research critical to ending AIDS epidemic

Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention and a founding member of the Global Health Technologies Coalition, writing in The Hill's "Congress Blog," welcomes Secretary of State Hillary Rodham Clinton's November 8 announcement of "an additional $60 million for implementation of a combination of prevention strategies in four sub-Saharan African countries and evaluation of their impact," adding that "this funding can only be viewed as a down payment on the work that needs to be done."

18 Nov 2011

HuffPost Green examines relationship between environment, malaria

As part of its series on the relationships between human, animal and environmental health, titled "The Infection Loop," HuffPost Green examines how changes in climate and landscape, human movement, agricultural practices, and microbe adaptation are affecting the spread of malaria.

18 Nov 2011

IAC executive director wins ECBT Immunization Leadership Award

The Immunization Action Coalition (IAC) is proud to announce that its executive director, Deborah Wexler, MD, has been selected as the honoree of the Every Child By Two Immunization Leadership Award. Every Child By Two (ECBT), founded by former First Lady Rosalynn Carter and former First Lady of Arkansas Betty Bumpers, is dedicated to protecting all children from vaccine-preventable diseases.

17 Nov 2011

IPS interviews head of Cuban research team working to develop dengue vaccine

Inter Press Service interviews Maria Guadalupe Guzman, head of the Pedro Kouri Institute (IPK) Department of Virology and director of the PAHO/WHO Collaborating Centre for the Study of Dengue and its Vector, who is leading of a team of Cuban researchers working to develop a vaccine against dengue.

17 Nov 2011

Non-therapeutic antibiotic usage in food animals creates resistance genes, promotes antibiotic resistance

In a review study, researchers from Tufts University School of Medicine zero in on the controversial, non-therapeutic use of antibiotics in food animals and fish farming as a cause of antibiotic resistance.

16 Nov 2011

Boehringer Ingelheim bolsters drug discovery, development with $350M in capital investments

Boehringer Ingelheim Pharmaceuticals announced today that it has made more than $350 million worth of capital investments throughout its U.S. operations this year, in order to further bolster its drug discovery, development and manufacturing capabilities.

16 Nov 2011

Streamlining clinical trials review process to speed up delivery of drugs to those in need

In this Atlantic opinion piece, Amanda Glassman, director of Global Health Policy at the Center for Global Development (CGD), reports on how lengthy, inefficient review processes for drug and vaccine candidates waiting in the pipeline for late stages of clinical development is keeping promising new medicines, vaccines, and diagnostic techniques from reaching millions in need.

16 Nov 2011

Study detects contrasting patterns of malaria drug resistance in humans, mosquitoes

A study conducted by researchers at the Johns Hopkins Malaria Research Institute and their Zambian colleagues detected contrasting patterns of drug resistance in malaria-causing parasites taken from both humans and mosquitoes in rural Zambia.

16 Nov 2011

IAVI policy brief examines HIV vaccine funding

A new policy brief from the International AIDS Vaccine Initiative (IAVI) "summarizes data on HIV vaccine R&D funding trends originally published by the HIV Vaccines and Microbicides Resource Tracking Working Group in 2011," according to the IAVI website.

16 Nov 2011

Some public health experts raise concerns over plans to immunize Haitians against cholera, AP reports

The Associated Press/Washington Times reports on a pilot project plan by Partners In Health (PIH) and GHESKIO to vaccinate Haitians against cholera, which "has set off a debate among some public health experts who question the wisdom of the program that will inoculate only one percent of the population and could deplete the world's stock of available cholera vaccine, potentially putting people at risk in other vulnerable places."

16 Nov 2011

Pneumococcal vaccine Prevnar13 effective in seniors

Pneumococcal disease kills millions worldwide and the largest affected groups are children and the elderly. Federal health scientists now assure that the popular pneumococcal vaccine Prevnar is at least as effective as a rival vaccine at protecting adults from the sometimes-deadly infection.

15 Nov 2011

Scientists determine atomic structure of Lassa fever viral protein

Scientists at The Scripps Research Institute have determined the atomic structure of a protein that the Lassa fever virus uses to make copies of itself within infected cells.

15 Nov 2011

Midatech receives Swissmedic approval to start trial of insulin-coated gold nanoparticle

Midatech Ltd., a global leader in the design, development, synthesis and manufacture of nanomedicines, announced today it has received Swissmedic approval to start the First-in-Human clinical trial with insulin-coated gold nanoparticles, which will be coordinated through its Swiss subsidiary PharMida AG.

15 Nov 2011

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that results from a Phase II trial (CTN-2006) in Stage III non-small cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy and an 8-year update from a phase I/II trial have been published in the November issue of Clinical Cancer, the journal of the American Association for Cancer Research.

15 Nov 2011